Triggering Receptor Expressed on Myeloid Cells Like 3: A Potential Drug Target and Biomarker

Target Name: TREML3P

NCBI ID: G340206

Other Name(s): Triggering receptor expressed on myeloid cells like 3, pseudogene | triggering receptor expressed on myeloid cells like 3, pseudogene | TREML3 | TLT3

Triggering Receptor Expressed on Myeloid Cells Like 3: A Potential Drug Target and Biomarker

Abstract:

Triggering receptor expressed on myeloid cells like 3 (TREML3P) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. This protein is expressed in high levels in myeloid cells, which are a critical part of the immune system and are involved in the development and progression of many diseases. In this article, we will discuss the discovery, function, and potential clinical applications of TREML3P as a drug target and biomarker.

Introduction:

Triggering receptor expressed on myeloid cells like 3 (TREML3P) is a protein that is expressed in high levels in myeloid cells, which are a type of white blood cell that plays a critical role in the immune system. Myeloid cells are responsible for the production of antibodies, which are proteins that help to neutralize toxins and pathogens in the body. TREML3P is a member of the TREM family of proteins, which are involved in the regulation of cellular processes such as cell growth, differentiation, and inflammation.

Discovery:

TREML3P was first identified in 2006 as a gene that is expressed in human myeloid cells, including leukemia cells. The gene was named based on the fact that it is located near the gene for triggering receptor expressed on mast cells, which is a protein that is involved in allergic reactions and inflammation.

Function:

TREML3P is a protein that is involved in several cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway. TGF-β is a signaling pathway that is involved in cell growth, differentiation, and inflammation, and it is a key regulator of TREML3P.

TREML3P is also involved in the regulation of cellular cytoskeleton, which is the structure that gives cells their shape and helps them to move and behave. The cytoskeleton is made up of a complex network of proteins that help to maintain the cell's shape and stability. TREML3P is involved in the regulation of the cytoskeleton by interacting with the protein tyrosine kinase, which is a protein that is involved in the regulation of many cellular processes, including cell growth, differentiation, and inflammation.

Potential Clinical Applications:

TREML3P is a potential drug target and biomarker for several diseases, including cancer. One of the main reasons for its potential as a drug target is its involvement in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and it is a key regulator of many diseases, including cancer.

TREML3P is also involved in the regulation of cellular cytoskeleton, which is the structure that gives cells their shape and helps them to move and behave. The cytoskeleton is made up of a complex network of proteins that help to maintain the cell's shape and stability. TREML3P is involved in the regulation of the cytoskeleton by interacting with the protein tyrosine kinase, which is a protein that is involved in the regulation of many cellular processes, including cell growth, differentiation, and inflammation.

In addition to its involvement in cellular signaling pathways and cytoskeleton regulation, TREML3P is also involved in the regulation of inflammation. Myeloid cells are a key part of the immune system, and they are involved in the production of antibodies, which are proteins that help to neutralize toxins and pathogens in the body. TREML3P is involved in the regulation of the production of antibodies by myeloid cells by interacting with the protein

Protein Name: Triggering Receptor Expressed On Myeloid Cells Like 3, Pseudogene

More Common Targets